Literature DB >> 11295066

Expression of Trk tyrosine kinase receptor is a biologic marker for cell proliferation and perineural invasion of human pancreatic ductal adenocarcinoma.

Y Sakamoto1, Y Kitajima, G Edakuni, E Sasatomi, M Mori, K Kitahara, K Miyazaki.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a widely known severe malignancy with a poor prognosis. Perineural invasion extending to the extra-pancreatic nerve plexus, a significant concern in the treatment is frequently present in this cancer. We analyzed immunohistochemical expression of neurotrophins (NGF, BDNF, NT-3) and the cognate receptors, Trk tyrosine kinase receptor family (TrkA, B, C) and p75NGFR in 28 surgically resected PDAC specimens. A comparative study between several clinicopathologic factors and Trk receptors revealed a significant correlation between increased expression of TrkA and cancer proliferation, as well as TrkC and cancer invasion, including venous and perineural invasion. The present findings revealed a novel mechanism in PDAC progression that is mediated via a NTs-Trk interaction.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11295066     DOI: 10.3892/or.8.3.477

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  TrkB inhibition by GNF-4256 slows growth and enhances chemotherapeutic efficacy in neuroblastoma xenografts.

Authors:  Jamie L Croucher; Radhika Iyer; Nanxin Li; Valentina Molteni; Jon Loren; W Perry Gordon; Tove Tuntland; Bo Liu; Garrett M Brodeur
Journal:  Cancer Chemother Pharmacol       Date:  2014-11-14       Impact factor: 3.333

Review 2.  How Schwann cells facilitate cancer progression in nerves.

Authors:  Sylvie Deborde; Richard J Wong
Journal:  Cell Mol Life Sci       Date:  2017-06-19       Impact factor: 9.261

3.  Methylation and expression patterns of tropomyosin-related kinase genes in different grades of glioma.

Authors:  Mahalakshmi Palani; R Arunkumar; Arrambakam Janardhanam Vanisree
Journal:  Neuromolecular Med       Date:  2014-05-20       Impact factor: 3.843

Review 4.  Mechanisms of cancer dissemination along nerves.

Authors:  Moran Amit; Shorook Na'ara; Ziv Gil
Journal:  Nat Rev Cancer       Date:  2016-05-06       Impact factor: 60.716

5.  Systemic Depletion of Nerve Growth Factor Inhibits Disease Progression in a Genetically Engineered Model of Pancreatic Ductal Adenocarcinoma.

Authors:  Jami L Saloman; Aatur D Singhi; Douglas J Hartman; Daniel P Normolle; Kathryn M Albers; Brian M Davis
Journal:  Pancreas       Date:  2018-08       Impact factor: 3.327

6.  Neurotrophin-3 production promotes human neuroblastoma cell survival by inhibiting TrkC-induced apoptosis.

Authors:  Jimena Bouzas-Rodriguez; Jorge Ruben Cabrera; Céline Delloye-Bourgeois; Gabriel Ichim; Jean-Guy Delcros; Marie-Anne Raquin; Raphaël Rousseau; Valérie Combaret; Jean Bénard; Servane Tauszig-Delamasure; Patrick Mehlen
Journal:  J Clin Invest       Date:  2010-02-15       Impact factor: 14.808

Review 7.  CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer.

Authors:  Timothy R Donahue; O Joe Hines
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

8.  The effect of brain-derived neurotrophic factor on angiogenesis.

Authors:  Chunyan Sun; Yu Hu; Zhangbo Chu; Jing Huang; Lu Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2009-04-28

9.  TRK-A, HER-2/neu, and KIT Expression/Activation Profiles in Salivary Gland Carcinoma.

Authors:  Tiziana Negri; Elena Tamborini; Gian Paolo Dagrada; Angela Greco; Samantha Staurengo; Marco Guzzo; Laura D Locati; Antonino Carbone; Marco A Pierotti; Lisa Licitra; Silvana Pilotti
Journal:  Transl Oncol       Date:  2008-09       Impact factor: 4.243

10.  Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model.

Authors:  Radhika Iyer; Lea Wehrmann; Rebecca L Golden; Koumudi Naraparaju; Jamie L Croucher; Suzanne P MacFarland; Peng Guan; Venkatadri Kolla; Ge Wei; Nicholas Cam; Gang Li; Zachary Hornby; Garrett M Brodeur
Journal:  Cancer Lett       Date:  2016-01-18       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.